New Delhi, April 21, 2025: BSE-Listed Aayush Wellness Limited (539528), a leading player in the Nutraceutical sector, has announced its strategic entry into the fast-growing diagnostic market. The company’s entry is driven by the adoption of advanced genomic testing technologies aimed at capturing India’s rapidly expanding $25 billion diagnostics industry share. Globally, the market is expected to reach $2729.8 billion by 2032.
This move is a key milestone in Aayush Wellness’s growth journey and is in line with growing demand for preventive healthcare. By integrating the diagnostics into the business model, the company plans to expand its offering and strengthen its commitment to overall health. The shift also complements the growing international presence of existing product lines, including the recent $3 million export agreement with Singapore-based COSMOS Holdings.
Founded in 1989 and certified under ISO 9000 and 22000, Aayush Wellness (BSE Code: 539528) specializes in Advanced Health and Wellness Solutions. As the Advanced Nutrition Company, it created its own name in the health and wellness industry. With its steady expansion into international markets, including Africa and Southeast Asia, product innovation and a solid domestic footprint, Aayush Wellness is an attractive proposition for investors.
With consistent revenue growth and a diagnostic foothold with the present and new era of DNA wellness testing technology, the company is well positioned to provide long-term shareholder value, making it a promising player for investors looking for future opportunities in integrated healthcare.
(This article is part of Indiadotcom Pvt Ltd’s Consumer Connect initiative, paid publishing program. IDPL does not claim editorial involvement and assumes liability, liability or claim for errors or omissions in the content of the article.)
